Mountain Crest Acquisiti... Aktie - MCAG

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

10,90

Gebot

10,72

Fragen

11,20

Volumen

0,00 Tagesbereich 0,00

10,47 52-Wochen-Bereich 11,50

Marktkapitalisierung

34,555M

Handelsende

10,90

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

3.170.221

Dividendenrendite

Kurs-Gewinn-Verhältnis

-15,35

Gewinn pro Aktie (EPS)

-0,71

Erlöse

Nettogewinn

-2,25M

Mountain Crest Acquisition Corp V is a blank check company. Mountain Crest Acquisition Corp V is a blank check company.

Sektor

Blank Checks

Branche

Blank Checks

Website

www.mcacquisition.com/mountain-crest-v-/default.aspx

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Mountain Crest Acquisition Corporation V is listed in the Blank Checks sector of the NASDAQ with ticker MCAG. The last closing price for Mountain Crest Acquisiti... was US$10,90. Over the last year, Mountain Crest Acquisiti... shares have traded in a share price range of US$ 10,47 to US$ 11,50.

Mountain Crest Acquisiti... currently has 3.170.221 shares in issue. The market capitalisation of Mountain Crest Acquisiti... is US$34,56 million. Mountain Crest Acquisiti... has a price to earnings ratio (PE ratio) of -15.35.

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Makes Progress Towards Regaining Compliance

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (the “Company”) (NASDAQ: MCAG), today announced that it...

CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed

NEW YORK, USA and SEOUL, Korea, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V, a...

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K and Quarterly Report on Form 10-Q

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ: MCAG, the “Company”) today announced that it received an...

CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V

NEW YORK, USA and SEOUL, Korea, May 02, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V, a Delaware corporation (“Mountain...

Mountain Crest Acquisition Corp. V Announces Listing Transfer to the Nasdaq Capital Market

NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) (the “Company”) announced today that it has...

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global...

AUM Biosciences to Participate in Inaugural EF Hutton Global Conference

SINGAPORE and BETHESDA, Md., April 26, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global...

AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma

SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global...

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

SINGAPORE and BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a...

AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit

SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	10.9	10.9	10.9	0	0	CS
4	0	0	10.9	10.9	10.9	0	0	CS
12	0	0	10.9	10.9	10.9	0	0	CS
26	-0.27	-2.41718889884	11.17	11.5	10.9	3244	11.34994893	CS
52	0.21	1.96445275959	10.69	11.5	10.47	2225	11.24501771	CS
156	1.08	10.9979633401	9.82	11.5	9.69	6580	10.1526634	CS
260	-1.1	-9.16666666667	12	12	9.69	8104	10.03959241	CS

MCAG - Frequently Asked Questions (FAQ)

What is the current Mountain Crest Acquisiti... share price?

The current share price of Mountain Crest Acquisiti... is US$ 10,90

How many Mountain Crest Acquisiti... shares are in issue?

Mountain Crest Acquisiti... has 3.170.221 shares in issue

What is the market cap of Mountain Crest Acquisiti...?

The market capitalisation of Mountain Crest Acquisiti... is USD 34,56M

What is the 1 year trading range for Mountain Crest Acquisiti... share price?

Mountain Crest Acquisiti... has traded in the range of US$ 10,47 to US$ 11,50 during the past year

What is the PE ratio of Mountain Crest Acquisiti...?

The price to earnings ratio of Mountain Crest Acquisiti... is -15,35

What is the reporting currency for Mountain Crest Acquisiti...?

Mountain Crest Acquisiti... reports financial results in USD

What is the latest annual profit for Mountain Crest Acquisiti...?

The latest annual profit of Mountain Crest Acquisiti... is USD -2,25M

What is the registered address of Mountain Crest Acquisiti...?

The registered address for Mountain Crest Acquisiti... is 1521 CONCORD PIKE, SUITE 201, WILMINGTON, DELAWARE, 19803

What is the Mountain Crest Acquisiti... website address?

The website address for Mountain Crest Acquisiti... is www.mcacquisition.com/mountain-crest-v-/default.aspx

Which industry sector does Mountain Crest Acquisiti... operate in?

Mountain Crest Acquisiti... operates in the BLANK CHECKS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
PTPIPetros Pharmaceuticals Inc	US$ 0,1684 (191,35%)	1,4B
OSRHOSR Holdings Inc	US$ 3,4299 (114,37%)	75,52M
OCEAOcean Biomedical Inc	US$ 0,12 (111,27%)	646,23M
VVPRVivoPower International PLC	US$ 3,98 (76,11%)	132,32M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,084 (66,01%)	252,68M
BACKIMAC Holdings Inc	US$ 0,0712 (-64,40%)	1,14M
ACRVAcrivon Therapeutics Inc	US$ 3,26 (-39,52%)	943,9k
BHILBenson Hill Inc	US$ 0,275746 (-34,87%)	826,6k
TNONTenon Medical Inc	US$ 2,5097 (-33,07%)	16,58M
HUMAHumacyte Inc	US$ 1,98 (-31,13%)	19,64M
PTPIPetros Pharmaceuticals Inc	US$ 0,1684 (191,35%)	1,4B
OCEAOcean Biomedical Inc	US$ 0,12 (111,27%)	646,23M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,084 (66,01%)	252,68M
NVDANVIDIA Corporation	US$ 113,1475 (-6,25%)	198,24M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,618 (-10,40%)	170,76M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Mountain Crest Acquisition Corporation V (MCAG)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Mountain Crest Acquisition Corporation V

MCAG Neueste Nachrichten

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Makes Progress Towards Regaining Compliance

CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K and Quarterly Report on Form 10-Q

CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V

Mountain Crest Acquisition Corp. V Announces Listing Transfer to the Nasdaq Capital Market

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

AUM Biosciences to Participate in Inaugural EF Hutton Global Conference

AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Makes Progress Towards Regaining Compliance

CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K and Quarterly Report on Form 10-Q

CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V

MCAG - Frequently Asked Questions (FAQ)

Beweger

MCAG Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Mountain Crest Acquisition Corporation V (MCAG) Börsenkurse

Mountain Crest Acquisition Corporation V (MCAG)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Mountain Crest Acquisition Corporation V

MCAG Neueste Nachrichten

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Makes Progress Towards Regaining Compliance

CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K and Quarterly Report on Form 10-Q

CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V

Mountain Crest Acquisition Corp. V Announces Listing Transfer to the Nasdaq Capital Market

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

AUM Biosciences to Participate in Inaugural EF Hutton Global Conference

AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Makes Progress Towards Regaining Compliance

CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K and Quarterly Report on Form 10-Q

CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V

MCAG - Frequently Asked Questions (FAQ)

Beweger

MCAG Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen